# Nuvig Therapeutics

> Nuvig Therapeutics is a clinical-stage biotech in the San Francisco Bay Area developing next-generation immune modulators for chronic autoimmune and inflammatory diseases. Founded in 2022 on research from The Rockefeller University, its lead candidate NVG-2089 is a first-in-class recombinant Fc fragment that engages type II Fc receptors to recapitulate the anti-inflammatory benefits of IVIg without immunosuppression or the supply constraints of plasma-derived products. The company raised a $161M Series B in December 2024 to push NVG-2089 into Phase 2 for CIDP and other indications.

- **Founded:** 2022
- **Headquarters:** Menlo Park, California, United States
- **Founders:** Pamela Conley (Cofounder & Chief Scientific Officer (founding CEO)), Greg Coffey (Cofounder & VP, Immunology & Clinical Translational Research), Jeffrey V. Ravetch (Cofounder & Scientific Advisor)
- **Team size:** ~24 employees
- **Products:** NVG-2089, Immunomodulation platform
- **Notable:** Raised $208M total across Series A and Series B, Closed a $161M Series B in December 2024 co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities and Norwest Venture Partners, Advanced NVG-2089 through Phase 1 with a safe, well-tolerated, dose-proportional profile and demonstrated target engagement

## Products & services

- **NVG-2089** — First-in-class recombinant Fc fragment immunomodulator targeting type II Fc receptors; designed to recapitulate the anti-inflammatory effects of IVIg without immunosuppression. In Phase 2 development for chronic inflammatory demyelinating polyneuropathy (CIDP) and other autoimmune indications.
- **Immunomodulation platform** — A recombinant, scalable and reproducible approach to recapitulating the effects of intravenous immunoglobulin (IVIg) without the downsides and supply limitations of donor-derived plasma products.

## Achievements

- Raised $208M total across Series A and Series B
- Closed a $161M Series B in December 2024 co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities and Norwest Venture Partners
- Advanced NVG-2089 through Phase 1 with a safe, well-tolerated, dose-proportional profile and demonstrated target engagement
- Dosed first patient in Phase 2 CIDP trial in May 2025
- Attracted a syndicate of major pharma-affiliated investors including Bayer, Sanofi and Bristol Myers Squibb

## Latest updates

- **2025-09** — David J. Woodhouse, Ph.D. appointed Chief Executive Officer; James Mackay named Independent Board Chair.
- **2025-05** — First patient dosed in the Phase 2 trial of NVG-2089 in CIDP.
- **2024-12** — Closed $161M Series B financing and announced progression to Phase 2 development.

## Links

- Website: https://nuvigtx.com
- LinkedIn: https://www.linkedin.com/company/nuvig-therapeutics-inc
- Twitter/X: https://twitter.com/nuvigtx

---

Profile page: https://yespress.io/nuvig-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-11